Loose Skin After GLP-1 Weight Loss: “Ozempic Butt”, Arms and Abdomen: When Surgery Is Considered

Scroll through any fitness forum this spring and you will find the same photo posted with the same anxious caption: a pair of jeans that used to strain at the seams now hanging in folds at the back. As of March 2026, searches for “Ozempic butt” have climbed alongside a simple demographic fact, millions of people who started GLP-1 medicines in 2023 and 2024 are now 18 to 30 months in, past the steep part of the curve, and looking at their bodies with a new kind of scrutiny. Viral clips promising to “spot who is on the shot” have poured fuel on it.

The phrase is catchy and a little unkind. What it describes is neither mysterious nor unique to these medicines. It is the same thing bariatric surgeons have seen for decades: fat leaves faster than skin can shrink, and muscle can go with it if nobody is minding the protein and the weights.

This piece explains what is actually happening to the buttocks, arms and abdomen, how strong the evidence is, what genuinely helps, and the point at which a surgeon might reasonably enter the conversation.

What is “Ozempic butt”, and is it really a side effect?

“Ozempic butt” is a social-media label, not a medical diagnosis. It describes the deflated, sagging or flattened appearance of the buttocks that some people notice after losing a large amount of weight on a GLP-1 receptor agonist. A GLP-1 receptor agonist is a medicine that mimics a gut hormone which slows stomach emptying and dampens appetite in the brain; semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are the best known.

The distinction matters because the medicines do not act on skin or on the buttocks at all. They reduce how much you eat. What follows is ordinary physiology: a sustained calorie deficit pulls energy out of fat stores everywhere, and the buttocks, in many people, are one of the largest stores. When that volume leaves quickly, the skin envelope that grew to accommodate it is left with less to hold.

Cleveland Clinic dermatologists and surgeons who have written about the phenomenon make the same point: the changes people call “Ozempic face” or “Ozempic butt” are the changes of rapid weight loss by any route: a very-low-calorie diet, bariatric surgery or illness would produce them too. The medicines simply made large, fast losses common enough to earn a nickname.

Three things combine to create the look. The first is fat loss under the skin, called subcutaneous fat. The second is loss of lean mass, muscle and other non-fat tissue, which is a normal companion of any significant weight loss unless it is actively resisted. The third is skin that has lost some of its elastin, the protein fibers that let skin snap back, so it drapes rather than hugs.

None of this means a person should be worried about their treatment. It means the conversation about body composition should start on day one, not month eighteen.

What changed recently to make this a talking point

Two dates anchor the current wave of interest. In February 2021, the STEP 1 trial of weekly semaglutide was published, showing an average weight loss of 14.9 percent over 68 weeks compared with 2.4 percent on placebo. In June 2022, the SURMOUNT-1 trial of tirzepatide reported losses of up to about 21 percent over 72 weeks on the highest studied dose. Those are figures previously seen only after bariatric surgery, and they came from an injection.

Approvals followed: semaglutide for chronic weight management in 2021 and tirzepatide in late 2023 in the United States, both now documented in MedlinePlus drug monographs. Prescriptions rose sharply through 2024 and 2025. The result, as of March 2026, is an unusually large cohort of adults who have lost 15 to 25 percent of their body weight in under two years, and who are now noticing what that does to skin.

Harvard Health’s consumer explainer on GLP-1 side effects added “Ozempic face” and related appearance changes to its coverage in 2024, noting explicitly that these are consequences of rapid weight loss rather than direct drug effects. Cleveland Clinic published a similar explainer on the buttocks specifically. When two large academic health systems address a slang term, that is a fair signal it has reached the exam room.

What has not changed is the science of skin. There is no new trial showing that GLP-1 medicines damage collagen or elastin. There is no guideline recommending a particular procedure for people on these medicines. Plastic surgeons report more consultations for body contouring after non-surgical weight loss, but that is observational and self-reported, not trial evidence.

The honest summary of “what changed” is therefore this: the medicines got much more effective and much more widely used, and the skin changes that always accompanied big weight loss became visible at population scale.

Why does rapid GLP-1 weight loss flatten the buttocks first?

Think of the buttocks as a cushion with three layers: skin, a thick pad of subcutaneous fat, and underneath it the gluteal muscles, gluteus maximus, medius and minimus. A rounded shape depends on all three being full. Weight loss on a GLP-1 medicine attacks two of them at once.

Fat comes out of the gluteal pad readily because the body does not choose where to burn fat; it draws down stores roughly in proportion to how much is there, modified by sex hormones and genetics. People who carry weight in the hips and buttocks, a distribution more common in women, will therefore see the largest absolute change in that region.

Muscle is the quieter loss. In any calorie deficit the body also breaks down some protein for energy, and the large postural muscles of the hips are not spared. Sitting most of the day, which many desk workers do, means the gluteals were already under-stimulated. Reduced appetite can also mean reduced protein intake without anyone intending it: a smaller plate is a smaller plate all the way round.

Skin is the layer that cannot keep up. Elastin fibers, which give skin its recoil, are laid down mostly in childhood and adolescence and are not replaced efficiently in adulthood. Collagen, the structural protein that gives skin strength, is remodeled slowly, over months to years. When the volume beneath the skin drops by a fifth in eighteen months, the envelope simply has not had time to contract. Gravity then does the rest, which is why the crease under the buttock deepens and the cheek appears to slide toward the thigh.

Age, sun exposure, smoking history, genetics and the number of years the skin spent stretched all influence how much recoil is possible. Two people losing identical weight can look very different afterwards for reasons that have nothing to do with effort.

What does “Ozempic bum” look like, and can you really tell who is on it?

People searching “what does Ozempic bum look like” are usually describing one of three patterns. The first is deflation: the cheeks look smaller and softer, and the natural fullness at the top of the buttock is gone. The second is a lower, longer crease where the buttock meets the thigh, sometimes with a fold of loose skin that can be pinched. The third is wrinkling or a crepey texture on the skin surface, more visible when standing than lying down.

Clothes often notice before mirrors do. Trousers that fit at the waist gap at the seat; a swimsuit that used to sit flat begins to ripple. These are cosmetic observations, not medical ones, and they carry no health meaning on their own.

The viral question, how can you tell if someone is on Ozempic, deserves a direct answer: you cannot, reliably, and it is not a respectful thing to try. Rapid weight loss from any cause produces the same changes in the face, buttocks and arms. Cancer treatment, bariatric surgery, a restrictive eating disorder, a new running habit and grief can all thin a face and flatten a backside. Assuming medication from appearance is guesswork dressed as insight.

Clinicians have no visual test either. There is no facial or body sign specific to GLP-1 medicines. What doctors do look for is the pace of loss and what came with it, dizziness, fatigue, hair shedding or muscle weakness, because those can signal that the deficit is too aggressive or protein intake too low, regardless of how the weight is coming off.

The kinder and more accurate reframing is this: what people call “Ozempic bum” is a visible marker that a large amount of weight left quickly. Whether that is cause for celebration, concern or a strength-training plan is a conversation for the person and their clinician, not for onlookers.

Ozempic belly: loose abdominal skin versus fat that has not gone yet

“Ozempic belly” is used online in two contradictory ways, and untangling them saves a lot of worry. Some people mean a belly that still looks large despite weight loss; others mean an apron of loose skin that folds over the waistband. The two have different causes and different answers.

Take the persistent bulge first. Abdominal fat sits in two compartments. Subcutaneous fat lies just under the skin and is what you can pinch. Visceral fat surrounds the organs inside the abdominal wall and cannot be pinched at all. Visceral fat tends to respond well to weight loss, but the subcutaneous layer on the lower abdomen is often the last store to shrink. A person who has lost 15 percent of their body weight may still have a soft lower belly simply because that region is at the back of the queue.

Bloating adds confusion. GLP-1 medicines slow stomach emptying, and constipation and gas are among the most commonly reported gastrointestinal effects in the MedlinePlus monographs for both semaglutide and tirzepatide. A distended, gassy abdomen in the evening is not fat and not loose skin; it is a digestive symptom worth mentioning to the prescriber.

Now the apron. After large losses, the lower abdominal skin, stretched for years, sometimes through pregnancies, hangs as a fold called a pannus. It may be small and purely cosmetic, or large enough to rub, chafe and trap moisture. That distinction is medical, not aesthetic, and it is the doorway to a surgical conversation covered later in this article.

A simple home observation helps sort things out: loose skin folds and can be lifted away from the body; fat cannot be lifted, only pinched; bloating changes across the day and after meals. Bringing that observation to an appointment turns a vague “Ozempic belly” complaint into something a clinician can actually assess.

Arms, thighs, face and chest: where else the skin shows the loss

The buttocks get the nickname, but the upper arms are where many people first feel self-conscious. The skin between shoulder and elbow has a thin subcutaneous layer, little muscle bulk in sedentary adults, and is constantly pulled downward by gravity when the arm is lifted. After significant weight loss it can hang as a fold that swings, sometimes called “bat wings”. Triceps training helps fill the space partially, but skin that has lost elasticity will not fully retract.

Inner thighs behave similarly. Fat here is soft and mobile, and the skin can become loose and wrinkled, occasionally chafing when walking. The face loses fat from the cheeks and temples, producing the hollowed look nicknamed “Ozempic face”; Harvard Health’s explainer attributes this squarely to rapid fat loss rather than any effect of the drug on facial tissue. In the chest, both men and women can see deflated or drooping tissue as the fat component shrinks.

The pattern is worth understanding because it dictates strategy. Regions with large underlying muscles, buttocks, thighs, shoulders, respond visibly to resistance training, because muscle can be grown to occupy some of the vacated space. Regions with little muscle beneath the skin, the upper arms, lower abdomen, face, cannot be “filled” by exercise to the same degree, and here the realistic options are time, acceptance or a surgical conversation.

Pace matters everywhere. Skin remodels slowly, and a loss spread over 24 months gives collagen more time to reorganize than the same loss in 9. Clinicians managing GLP-1 treatment generally aim for steady loss rather than the fastest possible, partly for this reason and partly because very rapid loss is associated with more lean-mass loss, gallstones and hair shedding.

Where the changes appear is largely genetic and hormonal. Where they can be softened is a question of muscle, protein, time and, occasionally, a scalpel.

What the evidence actually says, and how strong it is

Grading the evidence honestly means separating three claims that get blurred together online.

Claim one: GLP-1 medicines cause large, rapid weight loss. Evidence grade: strong, from randomised controlled trials. STEP 1 (semaglutide, 1,961 participants, 68 weeks) and SURMOUNT-1 (tirzepatide, 2,539 participants, 72 weeks) are large, placebo-controlled trials published in peer-reviewed journals and indexed on PubMed. The magnitude and pace of loss are not in dispute.

Claim two: a meaningful share of that loss is lean mass. Evidence grade: moderate. Both trials included sub-studies using DEXA, a dual-energy X-ray scan that measures fat, muscle and bone separately, in a subset of participants. In STEP 1, roughly 40 percent of the weight lost in the scanned group was lean mass; in SURMOUNT-1, about a quarter. These are sub-study figures from a few hundred people, not the full trial populations, and they do not distinguish skeletal muscle from water or organ tissue. They are consistent with what is known about weight loss by diet alone, where 20 to 30 percent lean loss is typical.

Claim three: the medicines directly damage skin or fat in the buttocks and face. Evidence grade: none. No randomised or observational study shows a drug-specific effect on collagen, elastin or fat distribution. Academic health systems including Cleveland Clinic and Harvard Health state that the appearance changes reflect rapid weight loss itself.

Claim four: resistance training and adequate protein preserve muscle during weight loss. Evidence grade: moderate to strong for weight loss in general, from randomised trials of diet plus exercise; limited but emerging specifically in people on GLP-1 medicines, where most data so far are small trials and observational reports.

Claim five: surgery reliably corrects loose skin after massive weight loss. Evidence grade: moderate, drawn mostly from observational surgical series after bariatric surgery. Outcomes are well described; randomised comparisons between procedures are rare.

The pattern is clear. The weight loss is proven; the body-composition concern is real but partly extrapolated; the drug-damages-skin idea has no support.

Is it fat loss or muscle loss? What the body-composition numbers mean

Imagine two people who each lose 20 kilograms. One loses 16 kilograms of fat and 4 of lean mass; the other loses 12 of fat and 8 of lean mass. On the bathroom scale they are identical. In a swimsuit, and on a leg-press machine, they are not. The first person’s buttocks and thighs keep more of their shape because the gluteal and thigh muscles have held their volume.

The DEXA sub-studies in the GLP-1 trials give a sense of where most people land. In STEP 1, participants scanned at 68 weeks had lost, on average, several kilograms of lean mass alongside a larger fat loss: a ratio of roughly 60 percent fat to 40 percent lean in that subgroup. SURMOUNT-1’s scanned participants lost about three-quarters fat and one-quarter lean. Both are within the range seen in older diet-only studies, which suggests the medicines are not uniquely muscle-wasting; they are producing a large deficit, and large deficits cost some muscle.

Two caveats keep this honest. Lean mass on DEXA includes water, organ tissue and connective tissue, not just muscle, and some lean-mass decline simply reflects the fact that a smaller body needs less supporting tissue. The sub-studies also did not measure strength or function, which matter more for daily life than a number on a scan.

What the numbers do justify is attention. Muscle is metabolically active, supports joints, buffers blood glucose and, relevant to this article, is the only tissue under the buttocks that can be deliberately enlarged. Preserving it turns a 40:60 split toward 25:75, and that difference is visible.

Practical levers, all supported by general weight-loss evidence rather than GLP-1-specific trials: eating protein at every meal, resistance training two or more days a week as the CDC activity guidelines recommend for all adults, and avoiding a pace of loss so fast that appetite suppression tips into under-eating. Any change to eating patterns while on these medicines should be discussed with the prescribing clinician, particularly for people with diabetes or kidney disease.

Will I lose my BBL on Ozempic? And what is “Mounjaro bum”?

A Brazilian butt lift, or BBL, is a cosmetic procedure in which a surgeon removes fat from one area by liposuction and injects it into the buttocks to add volume. The transferred fat that survives the procedure becomes living tissue with its own blood supply. It behaves like any other fat on the body, which is the crux of the answer.

Fat cells shrink when the body is in a calorie deficit. They do not know they were moved from the flank to the buttock. Someone who had a BBL and then loses 15 to 20 percent of their body weight on semaglutide or tirzepatide should expect the grafted fat to shrink along with fat everywhere else. The buttocks will likely become smaller and may lose the roundness the procedure created. Whether the result is “lost” depends on how much fat was grafted, how much weight is lost and the person’s expectations. This is the settled understanding among plastic surgeons; there are no trials specific to GLP-1 medicines after fat grafting, so the evidence grade is expert opinion built on basic physiology.

“Mounjaro bum” is simply the tirzepatide version of the same nickname. Tirzepatide acts on two gut-hormone receptors, GLP-1 and GIP, rather than one, and in SURMOUNT-1 produced somewhat larger average losses than semaglutide did in STEP 1. Larger losses can mean more visible deflation, but the mechanism is identical: fat and some muscle leave, skin lags behind. No study suggests tirzepatide affects skin or gluteal tissue differently.

People considering a BBL while planning to start a GLP-1 medicine, or considering a GLP-1 medicine after a BBL, should raise it with both the prescriber and the surgeon. Most surgeons prefer to graft fat only after weight has been stable, because grafted fat placed before a large loss is likely to shrink and the aesthetic outcome becomes unpredictable. That sequencing decision belongs to the clinicians involved, not to a forum.

Can you prevent Ozempic butt? What helps, what is unproven

Prevention is a strong word for something partly written in your genes and your skin’s history. “Reduce” is more honest. Four levers have reasonable evidence behind them; a fifth category has none.

Resistance training the glutes and thighs. Squats, lunges, hip thrusts, step-ups and deadlift variations load the gluteus maximus directly. Growing that muscle puts volume back under the skin. General weight-loss trials consistently show that people who lift during a deficit keep more lean mass than those who do cardio alone. Two to three sessions a week, progressing the load over time, is the standard framework; a physical therapist or qualified trainer can adapt it for joints that have carried extra weight for years.

Protein. Adequate protein spread across the day supports muscle retention when calories are low. Because GLP-1 medicines suppress appetite, protein-rich foods are often the first thing people skip. Prioritizing them at each meal is a dietary strategy that a registered dietitian or the prescriber can tailor, especially for people with kidney disease.

Pace. Slower loss gives skin more time to remodel and costs less muscle. Clinicians titrate these medicines gradually in part to manage this; the schedule is theirs to set, and no one should adjust it independently.

Skin basics. Not smoking, using sunscreen and keeping skin moisturized protect existing collagen and elastin. They do not rebuild what is gone, but they stop further loss.

Unproven category. Firming creams, collagen supplements, dry brushing and “skin-tightening” gadgets sold online have no trial evidence for meaningful retraction after large weight loss. Office-based radiofrequency or ultrasound treatments produce modest, temporary tightening in small studies of mild laxity; they are not a substitute for surgery when skin excess is significant.

The realistic goal is a backside that is smaller and firm rather than smaller and empty. Muscle does that. Nothing in a jar does.

Surgical options for loose skin after GLP-1 weight loss, compared

Body-contouring surgery is the umbrella term for procedures that remove excess skin and reshape what remains after major weight loss. It is elective, it leaves permanent scars, and it is generally considered only when weight has been stable for many months. The table summarizes the procedures most often discussed for the three regions in this article.

Procedure	Region	What it does	Typical scar	Notable considerations
Abdominoplasty (tummy tuck)	Abdomen	Removes excess lower-abdominal skin and fat; often tightens separated abdominal muscles	Hip to hip, low on the abdomen; sometimes around the navel	Cosmetic; Mayo Clinic lists seroma, poor wound healing and numbness among risks
Panniculectomy	Abdomen	Removes the hanging apron (pannus) only; no muscle tightening	Hip to hip	Often done for functional problems such as chafing and skin infections
Brachioplasty (arm lift)	Upper arms	Removes loose skin from elbow to armpit	Along the inner arm, visible with arms raised	Scar trade-off is significant; nerve irritation possible
Lower body lift	Abdomen, hips, buttocks, outer thighs	Circumferential removal of skin; lifts the buttocks and thighs	Around the entire waist	Longest recovery; usually reserved for massive weight loss
Gluteal lift with auto-augmentation	Buttocks	Lifts sagging buttock skin and repositions the person’s own tissue to restore fullness	Along the upper buttock or waistline	Uses existing tissue rather than implants; results depend on how much tissue remains
Buttock implants or fat grafting	Buttocks	Adds volume rather than removing skin	Small incisions	Grafted fat shrinks with further weight loss; implants carry infection and displacement risks

Evidence for these procedures comes largely from observational surgical series in people who lost weight through bariatric surgery. Complication rates in that literature are higher than for cosmetic surgery in never-obese patients, wound-healing problems and seromas are the most common, and they rise with smoking, diabetes and higher body mass index at the time of surgery. Whether any of this applies to a given person is a question only a consultation with a board-certified plastic surgeon and the prescribing clinician can answer.

When is surgery considered, and when is it too soon?

Surgeons who work with post-weight-loss patients tend to ask three questions before anything else, and the answers matter more than how much skin there is.

Is weight stable? The conventional threshold, carried over from bariatric practice, is a stable weight for at least six to twelve months. The logic is simple: skin removed now will hang again if another 10 kilograms leaves later, and a surgeon cannot predict the final shape of a body that is still changing. For people on GLP-1 medicines this raises a specific wrinkle. Weight can plateau on treatment and then change if the medicine is adjusted or stopped; the STEP and SURMOUNT extension studies showed substantial regain in many people after discontinuation. A frank conversation between surgeon and prescriber about the long-term plan is part of responsible timing.

Is the problem functional, cosmetic or both? A pannus that traps moisture, causes recurrent rashes or fungal infections, interferes with walking or hygiene, or produces back pain is a functional problem, and panniculectomy is frequently discussed on those grounds. Loose skin that bothers a person only in a mirror is cosmetic. Both are legitimate reasons to see a surgeon; they lead to different conversations and different procedures.

Is the person medically ready? Good nutrition, especially protein, iron and vitamin levels, supports wound healing, and appetite-suppressed patients can be quietly under-nourished. Smoking is a near-universal reason to postpone. Well-controlled blood glucose and blood pressure lower risk. Many surgeons also want to know how the anesthesia team will handle a GLP-1 medicine around the operation, because slowed stomach emptying is a consideration during sedation; that is a clinical decision made between the anesthesiologist and the prescriber, never by the patient alone.

Too soon looks like this: still losing, still adjusting treatment, still smoking, or hoping surgery will fix distress about the body that is really about something else. A good surgeon will say so. The best outcomes in the surgical literature come from patients who arrived stable, informed and with modest expectations about scars.

Common myths about Ozempic butt, corrected

The viral claims have outrun the facts. Here are the ones that circulate most, each set against what the evidence supports.

“The drug melts fat only from the face and butt.” False. GLP-1 medicines reduce appetite; they have no regional targeting. Fat leaves in proportion to where it was stored, shaped by genetics and hormones. The face and buttocks look most changed because they are the areas other people look at, and because their skin is either thin or heavily loaded.

“You can spot someone on Ozempic by their face or body.” Unsupported and unkind. Rapid weight loss from any cause, surgery, illness, a restrictive diet, bereavement, produces identical changes. No clinician can diagnose a medicine from a photograph.

“Collagen supplements will tighten the skin back up.” No trial shows that oral collagen produces meaningful retraction of skin loosened by major weight loss. Small studies suggest modest improvements in skin hydration in older adults; that is a different question.

“Loose skin means you lost weight the wrong way.” False. Skin laxity after large loss is expected by every route, including bariatric surgery. It reflects how long the skin was stretched, age, genetics and pace, not virtue.

“Squats will fix Ozempic butt.” Half true. Building the gluteal muscles restores volume beneath the skin and visibly improves shape in most people. It does not remove excess skin. Someone with significant laxity can be strong and still have folds.

“You should stop the medicine to save your looks.” Not a decision for a forum. Stopping is associated with substantial weight regain in trial extensions, and the medical reasons a person was prescribed treatment, diabetes control, cardiovascular risk, sleep apnea, have not gone away. Any change belongs in a conversation with the prescriber.

“Surgery is quick and scar-free.” False. Body-contouring procedures involve long scars and recovery measured in weeks. They can be transformative, and they are honest about their trade-offs when done by qualified surgeons.

When to see a doctor about skin, muscle or weight changes on a GLP-1 medicine

Loose skin on its own is not a medical emergency. Some of what travels alongside it can be, and some of it changes management. The prescribing clinician should hear about all of the following; every decision about the medicine itself rests with them.

Contact your clinician promptly if you notice:

• Rapid loss of strength, difficulty climbing stairs, rising from a chair or carrying groceries you managed a few months ago, which can signal excessive muscle loss or under-nutrition.
• Dizziness, fainting, a racing heart or persistent fatigue, especially if you are eating very little.
• Weight falling faster than your clinician expected, or below the range you agreed together.
• Skin folds that are red, raw, weeping, painful or smell, signs of intertrigo (a rash where skin rubs on skin) or fungal or bacterial infection, which need treatment and may bear on a surgical conversation.
• Persistent abdominal bloating, severe constipation or vomiting; these are known gastrointestinal effects of semaglutide and tirzepatide listed in MedlinePlus and should be assessed.
• Marked hair shedding, brittle nails or cracks at the corners of the mouth, which can reflect protein or micronutrient shortfalls.

Seek urgent care the same day if you have:

• Severe, persistent abdominal pain, with or without vomiting, which can indicate pancreatitis or gallbladder disease, both listed as serious risks in the drug monographs.
• Signs of dehydration you cannot correct, very dark urine, confusion, inability to keep fluids down.
• After any surgery: fever, spreading redness, increasing pain, a wound that opens, calf pain or shortness of breath.

Bring specifics: how much weight over how many months, what you are eating, how often you train, and photographs if skin changes are the concern. A clinician can arrange a DEXA scan or a dietitian referral, review the treatment plan, and, if skin excess is functional or distressing, refer to a plastic surgeon. Never stop, pause or alter a prescribed medicine to manage appearance without that discussion; the medical reasons for treatment do not disappear because a pair of jeans fits differently.

Frequently asked questions

What does Ozempic bum look like?

It usually looks like a smaller, softer backside with less fullness at the top of the cheek, a deeper or lower crease where the buttock meets the thigh, and sometimes a pinchable fold of loose skin or a crepey surface texture. Trousers tend to gap at the seat while fitting at the waist. These are cosmetic changes of rapid fat and some muscle loss, not a sign of harm.

How can you tell if someone is on Ozempic?

You cannot, and clinicians cannot either. Rapid weight loss from any cause, bariatric surgery, cancer treatment, a restrictive diet, illness or grief, produces the same hollowed face, flatter buttocks and looser arms. There is no visual sign specific to semaglutide or tirzepatide. Guessing someone’s medication from their appearance is speculation, and it can be hurtful to people losing weight for reasons they have not shared.

Will I lose my BBL if I take Ozempic?

Probably some of it. Fat grafted during a Brazilian butt lift becomes ordinary living fat, and it shrinks in a calorie deficit like fat anywhere else. A weight loss of 15 to 20 percent will usually reduce buttock volume, including the grafted portion. No trials have studied this specifically; the answer rests on basic physiology and surgeon experience. Discuss sequencing with both your prescriber and your surgeon.

What is Mounjaro bum?

It is the same phenomenon as Ozempic butt, attached to tirzepatide instead of semaglutide. Tirzepatide acts on two gut-hormone receptors and produced somewhat larger average weight losses in its trials, so deflation can be more visible, but the mechanism is identical: fat and some muscle leave the buttocks faster than skin can retract. There is no evidence that tirzepatide affects skin or gluteal tissue differently.

What causes Ozempic belly, and is it fat or loose skin?

It can be three different things. Lower-abdominal subcutaneous fat is often the last store to shrink, so a soft belly can persist after significant loss. Bloating and constipation are common gastrointestinal effects of these medicines and change through the day. A fold of loose skin that lifts away from the body is a pannus. Sorting out which applies is something a clinician can do at an appointment.

Does Ozempic cause muscle loss?

Any large weight loss costs some lean mass, and GLP-1 medicines are no exception. DEXA sub-studies in the semaglutide and tirzepatide trials found that roughly a quarter to 40 percent of weight lost was lean tissue, within the range seen with diet alone. Resistance training two or more days a week and adequate protein reduce that share. Dietary changes should be planned with the prescribing clinician or a dietitian.

Can loose skin after GLP-1 weight loss tighten on its own?

Partly, and slowly. Skin remodels collagen over months to years, so mild laxity often improves within one to two years of weight stabilizing, especially in younger people with no smoking history. Skin that was stretched for many years, or in older adults, retracts less. Elastin fibers lost in adulthood are not efficiently replaced, which is why significant excess usually does not fully resolve without surgery.

How long should weight be stable before body-contouring surgery?

Most plastic surgeons want six to twelve months of stable weight, a threshold carried over from bariatric surgery practice. Operating during ongoing loss risks new laxity afterward and makes the final shape unpredictable. For people on GLP-1 medicines, the surgeon and prescriber should also discuss the long-term treatment plan, because weight can change if the medicine is later adjusted. Timing is a joint clinical decision.

Do collagen supplements or firming creams help Ozempic butt?

No trial shows that oral collagen, topical creams, dry brushing or home devices produce meaningful tightening of skin loosened by major weight loss. Small studies of collagen supplements report modest gains in skin hydration in older adults, which is a different question. Office-based radiofrequency or ultrasound offer small, temporary improvements for mild laxity. Building gluteal muscle is the only non-surgical step with a visible effect on shape.

Should I stop Ozempic to avoid loose skin?

That is a decision for your prescribing clinician, not something to change on your own. Trial extension studies show substantial weight regain after stopping semaglutide or tirzepatide, and the medical reasons for treatment, glucose control, cardiovascular risk, sleep apnea, remain. If appearance changes are distressing, raise them; the clinician can review pace of loss, protein intake, strength training and, where appropriate, refer to a plastic surgeon.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.